BNP Paribas Financial Markets’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-12,542
| Closed | -$253K | – | 4290 |
|
|
2021
Q3 | $253K | Buy |
12,542
+9,942
| +382% | +$274K | ﹤0.01% | 2967 |
|
|
2021
Q2 | $97K | Sell |
2,600
-11,517
| -82% | -$353K | ﹤0.01% | 3051 |
|
|
2021
Q1 | $361K | Sell |
14,117
-324,870
| -96% | -$8.3M | ﹤0.01% | 2753 |
|
|
2020
Q4 | $7.47M | Buy |
338,987
+219,765
| +184% | +$4.84M | 0.01% | 937 |
|
|
2020
Q3 | $2.14M | Buy |
119,222
+106,795
| +859% | +$2.21M | ﹤0.01% | 1484 |
|
|
2020
Q2 | $316K | Sell |
12,427
-24,749
| -67% | -$533K | ﹤0.01% | 2292 |
|
|
2020
Q1 | $683K | Sell |
37,176
-30,924
| -45% | -$601K | ﹤0.01% | 2179 |
|
|
2019
Q4 | $1.5M | Buy |
68,100
+59,685
| +709% | +$1.2M | ﹤0.01% | 1828 |
|
|
2019
Q3 | $121K | Buy |
8,415
+2,442
| +41% | +$34.9K | ﹤0.01% | 3027 |
|
|
2019
Q2 | $94.1K | Sell |
5,973
-5,204
| -47% | -$70.8K | ﹤0.01% | 3069 |
|
|
2019
Q1 | $164K | Buy |
+11,177
| New | +$128K | ﹤0.01% | 2812 |
|
|
2018
Q4 | – | Sell |
-1,452
| Closed | -$22.2K | – | 4479 |
|
|
2018
Q3 | $22.2K | Sell |
1,452
-154
| -10% | -$2.24K | ﹤0.01% | 3370 |
|
|
2018
Q2 | $19.7K | Buy |
1,606
+1,574
| +4,919% | +$19.8K | ﹤0.01% | 3505 |
|
|
2018
Q1 | $306 | Hold |
32
| – | – | ﹤0.01% | 4129 |
|
|
2017
Q4 | $289 | Hold |
32
| – | – | ﹤0.01% | 4123 |
|
|
2017
Q3 | $184 | Hold |
32
| – | – | ﹤0.01% | 4147 |
|
|
2017
Q2 | $101 | Hold |
32
| – | – | ﹤0.01% | 4176 |
|
|
2017
Q1 | $109 | Hold |
32
| – | – | ﹤0.01% | 3997 |
|
|
2016
Q4 | $92 | Buy |
+32
| New | +$114 | ﹤0.01% | 4111 |
|
|
2016
Q1 | – | Sell |
-3,156
| Closed | -$37.5K | – | 3229 |
|
|
2015
Q4 | $37.5K | Buy |
3,156
+32
| +1% | +$366 | ﹤0.01% | 3002 |
|
|
2015
Q3 | $25.6K | Buy |
3,124
+1,868
| +149% | +$21.6K | ﹤0.01% | 3232 |
|
|
2015
Q2 | $17.5K | Buy |
1,256
+1,182
| +1,597% | +$21.7K | ﹤0.01% | 3126 |
|
|
2015
Q1 | $1.78K | Buy |
+74
| New | +$1.66K | ﹤0.01% | 3489 |
|
|
2014
Q4 | – | Sell |
-167
| Closed | -$2.13K | – | 3467 |
|
|
2014
Q3 | $2.13K | Buy |
167
+94
| +129% | +$1.42K | ﹤0.01% | 3937 |
|
|
2014
Q2 | $1.65K | Buy |
+73
| New | +$1.32K | ﹤0.01% | 3213 |
|
Other funds holding DRNA
BNP Paribas Financial Markets's DRNA Position: Q4 2021 in Review
BNP Paribas Financial Markets sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 12,542 shares — an estimated $253K sold.
BNP Paribas Financial Markets first reported a position in DRNA in Q2 2014 and held it in 25 quarters. The position peaked at $7.47M in Q4 2020. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- BNP Paribas Financial Markets reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- BNP Paribas Financial Markets sold 12,542 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $253K.
- BNP Paribas Financial Markets first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2014 and held it in 25 quarters.
- BNP Paribas Financial Markets's Dicerna Pharmaceuticals, Inc. position peaked at $7.47M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2021, filed 9 Feb 2022.